\
&
Contact us
\
&
Contact us
Published on | 3 years ago
ProgrammesThe amended version of the Horizon Europe Main Work Programme 2021-2022 has been published on 10 May 2022. You can find the latest versions per subprogramme on the NCP Flanders website: Navigate to the respective subprogramme page and the link is situated in the right hand column of the page (under the section 'Work Programme & Calls').
The Commission provides a seperate document with the history of the changes introduced for each of the subprogrammes. You can find the 'History of Changes' document also on the respective subprogramme pages on our website, again in the right hand column (under the section 'Related Links'). This document allows you to quickly grasp which changes have been introduced as compared to the previous version.
Source: the Funding & Tenders Portal
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
Security Digital, Industry & Space Cybersecurity
On 28 January 2026, the SECURE project has launched a first round of financial support measures to help small businesses achieve compliance with new cybersecurity requirements for their hardware and software products. This will allow micro, small and medium enterprises (MSMEs) to request co-funding to strengthen the cybersecurity of their hardware... read more
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
